Grand Rounds: Advancing Pediatric Oncology Care: Insights into Precision Medicine
05-10-2024
By William Brodwater, MD , Pediatric Hematology Oncology Fellow, Akron Children's Hospital, Akron, OH
Objectives (Educational Content) :
1. Explore the principles and fundamental concepts of precision medicine as applied to pediatric oncology. 2. Identify recent advancements and successes in precision medicine technologies. 3. Describe the challenges and limitations associated with implementing precision medicine approaches in pediatric oncology practice.
Target Audience:
General pediatricians, family physicians, nurse practitioners, physician assistants, social workers, psychologists, and nurses.
Identified Gap:
Childhood cancer incidence rates have been increasing since 1970 and although it has plateaued since 2010, the incidence has increased in teenagers by 1%/year. Pediatric cancer continues to be the leading cause of death after infancy. Conventional treatment and methodology is effective but precision medicine may be the key to optimize our pediatric cancer treatment and care. Therefore, although there are many barriers to implementing precision medicine widely for pediatric cancer treatment, efforts are being made to overcome these barriers to provide the optimal treatment for each pediatric cancer patient.
Estimated Time to Complete the Educational Activity:
1 hour(s)
Expiration Date for CE/CME Credit:
05-09-2025
Method of Participation in the Learning Process:
The learner will view the presentation, successfully complete a post-test and complete an activity evaluation.
Evaluation Methods:
All learners must successfully complete a post-test, as well as an activity evaluation, to claim CE/CME credit.
Disclosure:
The following presenters have identified that they have no financial relationships with any ineligible companies. William Brodwater, MD
Accreditation Statement:
Children’s Hospital Medical Center of Akron is accredited by the Ohio State Medical Association to provide continuing medical education for physicians.
CHMCA designates this enduring material activity for a maximum of 1.0 AMA PRA Category 1 Credit TM. Physicians should only claim the credit commensurate with the extent of their participation in the activity.
Bibliography:
Moskowitz, Craid H et al. “Five-year PFS from the AETHERA trial of brentuxiam ab vedotin for Hodgkin lymphomia at high risk of pression or relapse.” Blood vol. 132,25 (2018). Doi:10.1182/blood-2018-07-861641
Kalubai Vari, Khajapeer & Baskaran, Rajasekaran. (2015). Hsp90 Inhibitors for the Treatment of Chronic Myeloid Leukemia. Leukemia Research and Treatment. 2015. 1-16. 10.1155/2015/757694.
Foa, Robin and Sabina Chiaretti. “Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.” The New England Journal of Medicine vol. 386,25 (2022): 2399-2411. Doi:10.1056/NEJMra2113347
